LAVAL, QC, Dec. 17, 2014 /CNW Telbec/ - Valeant Canada today announced it has acquired the Canadian rights to Edarbi™ (azilsartan medoxomil) and Edarbyclor™ (azilsartan medoxomil and chlorthalidone), two products from Takeda Pharmaceutical International GmbH that have been approved by Health Canada, and are indicated for hypertension. The rights were acquired through a license, distribution and supply agreement between affiliates of Valeant Canada and Takeda Pharmaceutical International.
The licensing of these complementary products supports Valeant Canada's desire to meet patient treatment needs and to build on its current product offering to physicians in the cardio-metabolic field, which already includes Lodalis, Tiazac XC and Glumetza.
"The addition of these products to Valeant Canada's portfolio will help us increase our presence in the cardiovascular field in Canada, while solidifying our position as a leader in the pharmaceutical industry", said Richard Lajoie, Vice-President of the Pharma Business Unit at Valeant Canada.
"We are very pleased that the licensing of these products in Canada has been made with a strong partner active in the cardiovascular field that will be able to quickly bring the value of these treatments to Canadian patients," said Mike Egli, President of Takeda Canada Inc. "Takeda Canada is committed to bringing new treatments to Canadians in the four vital disease areas of oncology, gastrointestinal disorders, respiratory diseases and metabolic disorders. The Edarbi family of products remains a priority for a variety of Takeda's markets globally."
About hypertension
Hypertension, or high blood pressure, is the number one risk factor for stroke and a major risk factor for heart disease. Hypertension occurs when the blood pressure in the arteries is elevated and the heart has to work harder than normal to pump blood through the blood vessels. Hypertension can be caused by many factors such as age, ethnicity and gender.1 Diabetic people with hypertension are also much more likely to develop heart disease and/or experience a stroke at an earlier age.2 Other factors, such as diet, exercise and smoking can be changed through lifestyle changes to reduce risks of hypertension.1
About Takeda Pharmaceuticals International GmbH
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
The company has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 16th by global prescription sales. Areas of focus include cardiovascular, gastroenterology, oncology and vaccines.
Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Additional information about Takeda is available through its corporate website: www.takeda.com
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Canada can be found at www.valeantcanada.com.
The news release is available at www.cnw.ca.
References
_______________________________________
1 Heart and Stroke Foundation. www.heartandstroke.qc.ca
2 Canadian Diabetes Association. www.diabetes.ca
SOURCE: Valeant Canada
Media contact: Marie-Christine Garon, Valeant Canada, [email protected], 514 409-0031
Share this article